Compositions and methods to increase production of isothiocyanates
Compositions and methods for converting at least one glucosinolate to an isothiocyanate using Bacillus subtilis 839, Bacillus subtilis CO4_4, Pediococcus pentosaceus M3_H01, and/or Pediococcus pentosaceus M2_H12, or active variants thereof, are provided. Conversion of glucosinolates, such as glucoraphanin, to isothiocyanates, such as sulforaphane, leads to the stimulation of the Nrf2/Keap pathway and phase II enzymes, providing chemoprotective and anti-inflammatory effects. Accordingly, provided herein are compositions comprising Bacillus subtilis 839, Bacillus subtilis CO4_4, Pediococcus pentosaceus M3_H01, and/or Pediococcus pentosaceus M2_H12, or active variants thereof, for administration to subjects for increasing isothiocyanate (e.g., sulforaphane) production, increasing the expression of genes regulated by the Nrf2 transcription factor, including phase II enzymes, decreasing inflammation, and treating or preventing an inflammatory disorder or a cancer. The composition can comprise at least one glucosinolate or a plant, plant part or an extract thereof comprising glucosinolate(s).
1 . A capsule, granule, powder, or dust composition comprising
lyophilized spores, forespores, and/or cells of at least one of: Bacillus subtilis 839 of accession number NRRL No. B-67951, Bacillus subtilis C04-4 of accession number NRRL No. B-68014 , Pediococcus pentosaceus M3_H01 of accession number NRRL No. B-68013, or and Pediococcus pentosaceus M2_H12 of accession number NRRL No. B-68012.
2 . The composition of claim 1 , further comprising at least one glucosinolate.
3 . The composition of claim 2 , wherein said glucosinolate comprises glucoraphanin.
4 . The composition of claim 2 , further comprising at least one plant part or extract comprising said at least one glucosinolate.
5 . The composition of claim 4 , wherein said plant part or extract is from at least one cruciferous plant part or extract.
6 . A tablet comprising:
at least one glucosinolate and
lyophilized spores, forespores, and/or cells of at least one of:
Bacillus subtilis 839 of accession number NRRL No. B-67951 , Bacillus subtilis C04-4 of accession number NRRL No. B-68014 , Pediococcus pentosaceus M3_H01 of accession number NRRL No. B-68013, and Pediococcus pentosaceus M2_H12 of accession number NRRL No. B-68012.
7 . The tablet of claim 6 , wherein said at least one glucosinolate comprises glucoraphanin.
8 . The tablet of claim 6 , further comprising at least one plant part or extract comprising said at least one glucosinolate.
9 . The tablet of claim 8 , wherein said plant part or extract is from at least one cruciferous plant part or extract.
10 . A gel comprising
spores, forespores, and/or cells of at least one of; Bacillus subtilis 839 of accession number NRRL No. B-67951 , Bacillus subtilis C04-4 of accession number NRRL No. B-68014 , Pediococcus pentosaceus M3_H01 of accession number NRRL No. B-68013, and Pediococcus pentosaceus M2_H12 of accession number NRRL No. B-68012.
11 . The gel of claim 10 , further comprising at least one glucosinolate.
12 . The gel of claim 11 , wherein said at least one glucosinolate comprises glucoraphanin.
13 . The gel of claim 11 , further comprising at least one plant part or extract comprising said at least one glucosinolate.
14 . The gel of claim 13 , wherein said plant part or extract is from at least one cruciferous plant part or extract.
15 . The composition of claim 1 , wherein
the lyophilized spores, forespores, and/or cells are at least one of: Bacillus subtilis C04 4 of accession number NRRL No. B-68014 , Pediococcus pentosaceus M 3_H01 of accession number NRRL No. B-68013, er and Pediococcus pentosaceus M 2_H12 of accession number NRRL No. B-68012.